{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:24:34Z","timestamp":1785875074133,"version":"3.56.0"},"reference-count":102,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Alterations in the intestinal microbiota have been implicated in both irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). However, their biological significance and therapeutic implications differ substantially between the two conditions. Although dysbiosis is a common feature, the mechanisms by which alterations in the microbiota contribute to disease pathophysiology and clinical expression are distinct. Some pathways are more prominent in IBS (e.g., the gut\u2013brain axis), whereas others are more prominent in IBD (e.g., reduced microbial diversity). Equally important are pathways that appear to play a role exclusively in IBD [e.g., Adherent-invasive Escherichia coli (AIEC) and Paneth cells], as well as others that seem to be specific to IBS (e.g., mast cell activation). In IBD, microbiota changes are primarily linked to immune dysregulation, mucosal barrier impairment, and inflammation-driven pathways, whereas in IBS, they are mainly associated with functional disturbances mediated by neuroimmune signaling and microbial metabolites. Furthermore, several microbiome-associated biomarkers differ between these two diseases, and some are already assessed by international guidelines. Although the microbiota plays a key role in IBS and IBD pathophysiology, microbiome-based treatments remain limited, especially in IBD. There are clinically available treatments in IBS (e.g., rifaximin, low-FODMAP diet), but in IBD, only the probiotic VSL#3 is guideline-approved in ulcerative colitis pouchitis prophylaxis. Nevertheless, the dynamic nature of the microbiota continues to support the investigation of already studied (e.g., probiotics, fecal microbiota transplantation) and potential novel therapeutic approaches at the research level. The aim of this review is to compare the gut-microbiota-related pathophysiological pathways and biomarkers between IBS and IBD, to summarize the microbiome-related medications that have already been studied in both diseases, and to suggest new potential therapeutic options based on the gut microbiota.<\/jats:p>","DOI":"10.3390\/ph19050783","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:12:08Z","timestamp":1779455528000},"page":"783","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7790-7845","authenticated-orcid":false,"given":"Ploutarchos","family":"Pastras","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4489-1485","authenticated-orcid":false,"given":"Ioanna","family":"Aggeletopoulou","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Psalti","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-8209","authenticated-orcid":false,"given":"Christos","family":"Triantos","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-pharmtox-010919-023628","article-title":"Microbiota-Gut-Brain Axis: New Therapeutic Opportunities","volume":"60","author":"Clarke","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36967","DOI":"10.1007\/s11356-021-14593-z","article-title":"Microbiota\u2019s role in health and diseases","volume":"28","author":"Aleya","year":"2021","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-019-0965-1","article-title":"A new genomic blueprint of the human gut microbiota","volume":"568","author":"Almeida","year":"2019","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/s41564-021-00904-0","article-title":"Fetal meconium does not have a detectable microbiota before birth","volume":"6","author":"Kennedy","year":"2021","journal-title":"Nat. Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41577-023-00874-w","article-title":"Early-life interactions between the microbiota and immune system: Impact on immune system development and atopic disease","volume":"23","author":"Donald","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12974-019-1434-3","article-title":"Impact of microbiota on central nervous system and neurological diseases: The gut-brain axis","volume":"16","author":"Ma","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/cei.13400","article-title":"Interactions of the microbiota with the mucosal immune system","volume":"199","author":"Bain","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e70168","DOI":"10.1002\/mco2.70168","article-title":"Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy","volume":"6","author":"Shen","year":"2025","journal-title":"MedComm"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s10482-020-01474-7","article-title":"Human gut microbiota\/microbiome in health and diseases: A review","volume":"113","author":"Gomaa","year":"2020","journal-title":"Antonie Leeuwenhoek"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","article-title":"Microbiota-gut-brain axis and its therapeutic applications in neurodegenerative diseases","volume":"9","author":"Loh","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.5009\/gnl230396","article-title":"Epidemiology of Disorders of the Gut-Brain Interaction: An Appraisal of the Rome IV Criteria and Beyond","volume":"18","author":"Ray","year":"2024","journal-title":"Gut Liver"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Aggeletopoulou, I., Papantoniou, K., Pastras, P., and Triantos, C. (2025). Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262110598"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"723","DOI":"10.5812\/ircmj.4605","article-title":"Health Related Quality of Life in Iranian Patients with Irritable Bowel Syndrome: Reliability and Validity of the Persian Version of the IBS-QOL","volume":"15","author":"Jafari","year":"2013","journal-title":"Iran. Red Crescent Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Katsoula, A., Axiaris, G., Mpitouli, A., Palatianou, M., Christidou, A., Dimitriadis, N., Nakos, A., Pastras, P., Kourkoulis, P., and Karatzas, P. (2023). The Inflammatory Bowel Disease-Disk Tool for Assessing Disability in Inflammatory Bowel Disease Patients: Validation of the Greek Version. J. Clin. Med., 12.","DOI":"10.3390\/jcm12083023"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, J., Han, X., Jiang, H., Zhang, L., Hu, J., Shi, L., and Li, J. (2022). Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.994619"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17562848231207312","DOI":"10.1177\/17562848231207312","article-title":"Latin America consensus statement inflammatory bowel disease: Importance of timely access to diagnosis and treatment","volume":"16","author":"Steinwurz","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"103498","DOI":"10.1016\/j.autrev.2023.103498","article-title":"Global, regional, and national burden of inflammatory bowel disease and its associated anemia, 1990 to 2019 and predictions to 2050: An analysis of the global burden of disease study 2019","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/gutjnl-2023-329948","article-title":"The first international Rome consensus conference on gut microbiota and faecal microbiota transplantation in inflammatory bowel disease","volume":"72","author":"Lopetuso","year":"2023","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/jgh.16795","article-title":"Gut microbiome-targeted therapies as adjuvant treatments in inflammatory bowel diseases: A systematic review and network meta-analysis","volume":"40","author":"Zhang","year":"2025","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/j.gastro.2023.07.018","article-title":"Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis","volume":"165","author":"Goodoory","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"eaap8914","DOI":"10.1126\/scitranslmed.aap8914","article-title":"Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome","volume":"10","author":"Imhann","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000477205","article-title":"Gut Microbiota in Health, Diverticular Disease, Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of Gastrointestinal Disorders","volume":"36","author":"Lopetuso","year":"2018","journal-title":"Dig. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Li, X., Yuan, Q., Huang, H., and Wang, L. (2025). Gut microbiota in irritable bowel syndrome: A narrative review of mechanisms and microbiome-based therapies. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1695321"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Xie, H., Yu, S., Tang, M., Xun, Y., Shen, Q., and Wu, G. (2025). Gut microbiota dysbiosis in inflammatory bowel disease: Interaction with intestinal barriers and microbiota-targeted treatment options. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1608025"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Santana, P.T., Rosas, S.L.B., Ribeiro, B.E., Marinho, Y., and de Souza, H.S.P. (2022). Dysbiosis in Inflammatory Bowel Disease: Pathogenic Role and Potential Therapeutic Targets. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073464"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cheng, X., Ren, C., Mei, X., Jiang, Y., and Zhou, Y. (2024). Gut microbiota and irritable bowel syndrome: Status and prospect. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1429133"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Qiu, P., Ishimoto, T., Fu, L., Zhang, J., Zhang, Z., and Liu, Y. (2022). The Gut Microbiota in Inflammatory Bowel Disease. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.733992"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gutjnl-2011-301501","article-title":"An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota","volume":"61","author":"Jeffery","year":"2012","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40168-022-01450-5","article-title":"Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes","volume":"11","author":"Jacobs","year":"2023","journal-title":"Microbiome"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.1038\/ncomms7734","article-title":"Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome","volume":"6","author":"Macia","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Parada Venegas, D., De la Fuente, M.K., Landskron, G., Gonz\u00e1lez, M.J., Quera, R., Dijkstra, G., Harmsen, H.J.M., Faber, K.N., and Hermoso, M.A. (2019). Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01486"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.3945\/jn.109.104638","article-title":"Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers","volume":"139","author":"Peng","year":"2009","journal-title":"J. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cgh.2018.08.054","article-title":"The Gut Microbiome in Adult and Pediatric Functional Gastrointestinal Disorders","volume":"17","author":"Shin","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41540-021-00178-6","article-title":"Metabolic modelling reveals broad changes in gut microbial metabolism in inflammatory bowel disease patients with dysbiosis","volume":"7","author":"Heinken","year":"2021","journal-title":"npj Syst. Biol. Appl."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1053\/j.gastro.2023.02.022","article-title":"The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases","volume":"164","author":"Fogelson","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"628157","DOI":"10.1155\/2015\/628157","article-title":"Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut","volume":"2015","author":"Michielan","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13238-020-00745-3","article-title":"The microbiome in inflammatory bowel diseases: From pathogenesis to therapy","volume":"12","author":"Liu","year":"2021","journal-title":"Protein Cell."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1053\/j.gastro.2021.06.024","article-title":"Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative Colitis","volume":"161","author":"Baumgartner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Yuan, C., He, Y., Xie, K., Feng, L., Gao, S., and Cai, L. (2023). Review of microbiota gut brain axis and innate immunity in inflammatory and infective diseases. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1282431"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Aggeletopoulou, I., and Triantos, C. (2024). Microbiome Shifts and Their Impact on Gut Physiology in Irritable Bowel Syndrome. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252212395"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1136\/gutjnl-2021-325985","article-title":"Bidirectional brain-gut axis effects influence mood and prognosis in IBD: A systematic review and meta-analysis","volume":"71","author":"Fairbrass","year":"2022","journal-title":"Gut"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1172\/JCI30504","article-title":"CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease","volume":"117","author":"Barnich","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"eesp00182022","DOI":"10.1128\/ecosalplus.esp-0018-2022","article-title":"Characterizing the Pathogenic Potential of Crohn\u2019s Disease-Associated Adherent-Invasive Escherichia coli","volume":"11","author":"Zangara","year":"2023","journal-title":"EcoSal Plus"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2172669","DOI":"10.1080\/19490976.2023.2172669","article-title":"The multifaceted virulence of adherent-invasive Escherichia coli","volume":"15","author":"Mansour","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2587402","DOI":"10.1080\/19490976.2025.2587402","article-title":"Persistence mechanisms of Crohn\u2019s disease-associated adherent invasive Escherichia coli within macrophages","volume":"17","author":"Bruder","year":"2025","journal-title":"Gut Microbes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.chom.2021.01.002","article-title":"Adherent-invasive E. coli metabolism of propanediol in Crohn\u2019s disease regulates phagocytes to drive intestinal inflammation","volume":"29","author":"Viladomiu","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI46333","article-title":"Adherent-invasive E. coli in Crohn disease: Bacterial \u201cagent provocateur\u201d","volume":"121","author":"Strober","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.14309\/ajg.0000000000001997","article-title":"Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes","volume":"117","author":"Leite","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"190","DOI":"10.14309\/ajg.0000000000000504","article-title":"Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Case-Control Studies","volume":"115","author":"Shah","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"322","DOI":"10.26444\/aaem\/193103","article-title":"Relationship between SIBO and other bowel diseases and a common eating pattern for them. Part III","volume":"31","author":"Kaczoruk","year":"2024","journal-title":"Ann. Agric. Environ. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Pimentel, M., Morales, W., Rezaie, A., Marsh, E., Lembo, A., Mirocha, J., Leffler, D.A., Marsh, Z., Weitsman, S., and Chua, K.S. (2015). Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126438"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1007\/s10620-017-4585-z","article-title":"Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome","volume":"62","author":"Rezaie","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e00064","DOI":"10.14309\/ctg.0000000000000064","article-title":"Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations with Functional Dyspepsia and Irritable Bowel Syndrome","volume":"10","author":"Talley","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e13666","DOI":"10.1111\/eci.13666","article-title":"Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID)","volume":"51","author":"Vasapolli","year":"2021","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e14339","DOI":"10.1111\/nmo.14339","article-title":"Mast cell mediation of visceral sensation and permeability in irritable bowel syndrome","volume":"34","author":"Hasler","year":"2022","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2006.11.039","article-title":"Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome","volume":"132","author":"Barbara","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5056\/jnm15137","article-title":"Mast Cells and Irritable Bowel Syndrome: From the Bench to the Bedside","volume":"22","author":"Zhang","year":"2016","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/eji.201847504","article-title":"Mast cells at the crossroads of microbiota and IBD","volume":"48","author":"Frossi","year":"2018","journal-title":"Eur. J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"D\u2019Inc\u00e0, R., and Sturniolo, G. (2023). Biomarkers in IBD: What to Utilize for the Diagnosis?. Diagnostics, 13.","DOI":"10.20944\/preprints202308.0749.v1"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohn\u2019s Colitis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"35375","DOI":"10.1038\/s41598-025-19363-2","article-title":"Microbiota and short chain fatty acid relationships underlie clinical heterogeneity and identify key microbial targets in irritable bowel syndrome (IBS)","volume":"15","author":"Shin","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jare.2025.05.015","article-title":"The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity","volume":"80","author":"He","year":"2026","journal-title":"J. Adv. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-025-60233-2","article-title":"Metabolic modeling reveals a multi-level deregulation of host-microbiome metabolic networks in IBD","volume":"16","author":"Taubenheim","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: A narrative review","volume":"19","author":"Petito","year":"2024","journal-title":"Intern. Emerg. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1053\/j.gastro.2015.08.006","article-title":"Diagnostic and Prognostic Microbial Biomarkers in Inflammatory Bowel Diseases","volume":"149","author":"Dubinsky","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1053\/j.gastro.2010.11.058","article-title":"The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease","volume":"140","author":"Lewis","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41591-024-03280-4","article-title":"Noninvasive, microbiome-based diagnosis of inflammatory bowel disease","volume":"30","author":"Zheng","year":"2024","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG Clinical Guideline: Management of Irritable Bowel Syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.18203\/2349-3933.ijam20243824","article-title":"Visceral hypersensitivity and diagnostic markers in functional gastrointestinal disorders: Expert opinion","volume":"12","author":"Mehrotra","year":"2025","journal-title":"Int. J. Adv. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.12688\/f1000research.52086.1","article-title":"Study of Antibodies to Cytolethal Distending Toxin B (CdtB) and Antibodies to Vinculin in Patients with Irritable Bowel Syndrome","volume":"10","author":"Zaki","year":"2021","journal-title":"F1000Research"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gtc.2025.08.002","article-title":"Biomarkers in Irritable Bowel Syndrome: Rationale and Practical Use","volume":"55","author":"Guan","year":"2026","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.gastro.2024.01.008","article-title":"AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases","volume":"166","author":"Peery","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0016-5085(03)00171-9","article-title":"Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial","volume":"124","author":"Gionchetti","year":"2003","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/ajg.2010.218","article-title":"Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study","volume":"105","author":"Tursi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1053\/j.gastro.2020.12.040","article-title":"Ulcerative colitis\u2014Maintanance of Remission with the Probiotic Escherichia coli Strain Nissle 1917","volume":"160","author":"Stange","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/gut.51.3.405","article-title":"Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn\u2019s disease: A randomised controlled trial with Lactobacillus GG","volume":"51","author":"Prantera","year":"2002","journal-title":"Gut"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ibd\/izad195","article-title":"Management of Perianal Fistulizing Crohn\u2019s Disease","volume":"30","author":"Singh","year":"2024","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2468-1253(21)00214-4","article-title":"Treatment of pouchitis, Crohn\u2019s disease, cuffitis, and other inflammatory disorders of the pouch: Consensus guidelines from the International Ileal Pouch Consortium","volume":"7","author":"Shen","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1756284819897531","DOI":"10.1177\/1756284819897531","article-title":"Mechanism of action and therapeutic benefit of rifaximin in patients with IBS: A narrative review","volume":"13","author":"Chey","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation","volume":"364","author":"Pimentel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1053\/j.gastro.2016.08.003","article-title":"Repeat Treatment with Rifaximin Is Safe and Effective in Patients with Diarrhea-Predominant Irritable Bowel Syndrome","volume":"151","author":"Lembo","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.gastro.2022.04.017","article-title":"AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome with Diarrhea","volume":"163","author":"Lembo","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrgastro.2017.88","article-title":"Gut microbiota and IBD: Causation or correlation?","volume":"14","author":"Ni","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.21037\/atm-22-3236","article-title":"Efficacy and safety of fecal microbiota transplantation for the induction of remission in active ulcerative colitis: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wei","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2018.20046","article-title":"Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients with Ulcerative Colitis: A Randomized Clinical Trial","volume":"321","author":"Costello","year":"2019","journal-title":"JAMA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1007\/s13197-015-1921-1","article-title":"Probiotics, prebiotics and synbiotics\u2014A review","volume":"52","author":"Pandey","year":"2015","journal-title":"J. Food Sci. Technol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Stange, E.F. (2024). Dysbiosis in inflammatory bowel diseases: Egg, not chicken. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1395861"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Feng, J.J., Maddirala, N.R., Saint Fleur, A., Zhou, F., Yu, D., Wei, F., and Zhang, Y. (2025). Gut Microbiome and Immune System Crosstalk in Chronic Inflammatory Diseases: A Narrative Review of Mechanisms and Therapeutic Opportunities. Microorganisms, 13.","DOI":"10.3390\/microorganisms13112516"},{"key":"ref_94","unstructured":"Reed, C. (2026, April 05). AGA Does Not Recommend the Use of Probiotics for Most Digestive Conditions. American Gastroenterological Association [Internet]. 9 June 2020. Available online: https:\/\/gastro.org\/press-releases\/aga-does-not-recommend-the-use-of-probiotics-for-most-digestive-conditions\/."},{"key":"ref_95","unstructured":"Oliero, M. (2026, April 05). Paving the Way for Microbiome-Based Therapy in Clinical Practice. Gut Microbiota for Health [Internet]. 14 July 2025. Available online: https:\/\/www.gutmicrobiotaforhealth.com\/paving-the-way-for-microbiome-based-therapy-in-clinical-practice\/."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Tannous, S., Husein, D.M., and Naim, H.Y. (2025). Congenital sucrase-isomaltase mutations worsen IBS-linked V15F dysfunction and trafficking. Gut.","DOI":"10.1136\/gutjnl-2025-336813"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kafentzi, T., Tsounis, E.P., Tourkochristou, E., Avramopoulou, E., Aggeletopoulou, I., Geramoutsos, G., Sotiropoulos, C., Pastras, P., Thomopoulos, K., and Theocharis, G. (2025). Genetic Polymorphisms (ApaI, FokI, BsmI, and TaqI) of the Vitamin D Receptor (VDR) Influence the Natural History and Phenotype of Crohn\u2019s Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26051848"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00281-025-01066-5","article-title":"Emerging microbiome-directed therapies in inflammatory bowel disease: Beyond diet modification and FMT","volume":"47","author":"Atanasova","year":"2025","journal-title":"Semin. Immunopathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.15419\/35b1xn36","article-title":"Insights into microbiome-based therapeutics: Engineered probiotics, bacteriophages, and microbiome-derived metabolites","volume":"12","author":"Yahya","year":"2025","journal-title":"Biomed. Res. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2232143","DOI":"10.1080\/19490976.2023.2232143","article-title":"Gut microbiota-related bile acid metabolism-FXR\/TGR5 axis impacts the response to anti-\u03b14\u03b27-integrin therapy in humanized mice with colitis","volume":"15","author":"Han","year":"2023","journal-title":"Gut Microbes"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40265-024-02107-3","article-title":"The Future of Microbiome Therapeutics","volume":"85","author":"Pitashny","year":"2025","journal-title":"Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2489067","DOI":"10.1080\/19490976.2025.2489067","article-title":"Precision microbiota therapy for IBD: Premise and promise","volume":"17","author":"Nagayama","year":"2025","journal-title":"Gut Microbes"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:21:15Z","timestamp":1779456075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/5\/783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":102,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ph19050783"],"URL":"https:\/\/doi.org\/10.3390\/ph19050783","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]}}}